Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 28
- Jul 1, 2023
Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab(anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Bullock, et al.
Filter by
Balstilimab (PD-1 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 3
- Jun 7, 2021
Differentiated Activity Profile for the PD-1 Inhibitor Balstilimab.
C.Joyce, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 9
- Apr 14, 2021
Fc-enhanced anti-CTLA-4 Antibody, AGEN1181: New Mechanistic Insights for Potent Antitumor Immunity and Combination Potential in Treatment-resistant Solid Tumors.
Tanne, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 9
- Apr 14, 2021
Characterization of The Pharmacodynamic Activity of AGEN1181, an Fc-enhanced CTLA-4 Antibody, Alone and in Combination With the PD-1 Antibody Balstilimab.
Shapiro, et al.
Balstilimab (PD-1 Antagonist)
SGO 2021 Virtual Annual Meetings on Women’s Cancer Abstracts
Mar 19
- Mar 22, 2021
RaPiDS (GOG-3028): A Randomized Phase II Studyof Balstilimab (AGEN2034) as Monotherapy or in Combination with Zalifrelimab (AGEN1884) in Second-Line Cervical Cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)
Oncogene
Jan 26, 2021
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.
Grossman, et al.
VISION
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro.
Pabla, et al.